AbbVie (ABBV) EPS (Basic) (2012 - 2026)

AbbVie has disclosed EPS (Basic) across 15 years of filings, most recently posting $0.39 for Q1 2026.

• In Q1 2026, EPS (Basic) fell 45.99% year-over-year to $0.39; the TTM figure through Mar 2026 stood at $2.06 (down 13.47% YoY), while the FY2025 annual figure was $2.39, down 1.24% from the prior year.
• EPS (Basic) retreated to $0.39 in Q1 2026, from $1.03 in the prior quarter.
• Over the last five years, EPS (Basic) for ABBV reached as high as $2.54 in Q1 2022 and fell as low as -$0.05 in Q1 2023.
• The 5-year median for EPS (Basic) is $0.78 (2024), against an average of $0.85.
• Annual changes were most pronounced in 2024 — EPS (Basic) sank 102.79% — and 2025, when it surged 7991.3%.
• A 5-year view of EPS (Basic) shows it stood at $1.4 in 2022, then sank by 66.61% to $0.47 in 2023, then slumped by 102.79% to -$0.01 in 2024, then surged by 7991.3% to $1.03 in 2025, then plunged by 61.62% to $0.39 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $0.39, $1.03, and $0.11 for Q1 2026, Q4 2025, and Q3 2025 respectively.